Loading
A phase 3 trial of Carboplatin and Etoposide in neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting.
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy is a phase 3 interventional study registered as NCT07544654 by Boehringer Ingelheim, with 390 participants planned, started 2026-07-10 and due to reach its primary completion in 2029-12-13. Interventions recorded: Obrixtamig, Carboplatin, Etoposide and Ventana DLL3 RxDx assay.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Obrixtamig, Boehringer Ingelheim, Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Shares Obrixtamig, Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/